Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Krystal Biotech (KRYS) and Veeva Systems (VEEV)
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements
Stifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
Optimistic Outlook for Lexeo Therapeutics With Strong Clinical and Financial Performance Justifying Buy Rating
Lexeo Therapeutics Analyst Ratings
RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy From Stifel Nicolaus
Analysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO) and Andlauer Healthcare Group (OtherANDHF)
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy From RBC Capital
RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts
JP Morgan Initiates Coverage On Lexeo Therapeutics With Overweight Rating, Announces Price Target of $20
Lexeo Therapeutics Analyst Ratings
No Data